| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
|
N Engl J Med
|
2012
|
4.49
|
|
2
|
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
|
Eur Heart J
|
2006
|
3.10
|
|
3
|
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
|
Lancet
|
2013
|
2.22
|
|
4
|
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
|
J Am Coll Cardiol
|
2008
|
1.83
|
|
5
|
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
|
J Clin Pharmacol
|
2008
|
1.80
|
|
6
|
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
|
Pharmacotherapy
|
2008
|
1.77
|
|
7
|
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
|
Am Heart J
|
2007
|
1.73
|
|
8
|
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
|
Circulation
|
2005
|
1.71
|
|
9
|
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
|
Eur Heart J
|
2007
|
1.61
|
|
10
|
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
|
Eur Heart J
|
2009
|
1.27
|
|
11
|
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
|
Am Heart J
|
2006
|
1.26
|
|
12
|
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.
|
J Clin Pharmacol
|
2008
|
1.20
|
|
13
|
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
|
Cardiovasc Drug Rev
|
2007
|
1.20
|
|
14
|
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
|
Thromb Haemost
|
2008
|
1.13
|
|
15
|
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
|
Clin Ther
|
2010
|
0.97
|
|
16
|
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
|
J Cardiovasc Pharmacol
|
2007
|
0.97
|
|
17
|
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
|
Eur J Clin Pharmacol
|
2009
|
0.97
|
|
18
|
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.
|
Br J Clin Pharmacol
|
2006
|
0.96
|
|
19
|
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
|
Thromb Haemost
|
2008
|
0.95
|
|
20
|
Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.
|
J Clin Pharmacol
|
2010
|
0.93
|
|
21
|
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
|
J Hematol Oncol
|
2013
|
0.93
|
|
22
|
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
|
Platelets
|
2006
|
0.93
|
|
23
|
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
|
Curr Med Res Opin
|
2008
|
0.92
|
|
24
|
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
|
J Am Coll Cardiol
|
2012
|
0.91
|
|
25
|
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
|
J Am Coll Cardiol
|
2013
|
0.90
|
|
26
|
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
|
Am J Cardiol
|
2007
|
0.90
|
|
27
|
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
|
J Am Coll Cardiol
|
2012
|
0.90
|
|
28
|
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
|
Platelets
|
2008
|
0.88
|
|
29
|
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
|
Am Heart J
|
2009
|
0.87
|
|
30
|
Clopidogrel poor responders: an objective definition based on Bayesian classification.
|
Platelets
|
2007
|
0.86
|
|
31
|
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
|
Platelets
|
2009
|
0.86
|
|
32
|
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
|
J Cardiovasc Pharmacol
|
2007
|
0.85
|
|
33
|
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
|
J Pharmacokinet Pharmacodyn
|
2008
|
0.85
|
|
34
|
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
|
Circulation
|
2013
|
0.85
|
|
35
|
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
|
Platelets
|
2006
|
0.84
|
|
36
|
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
|
Br J Clin Pharmacol
|
2012
|
0.84
|
|
37
|
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
|
Thromb Haemost
|
2008
|
0.82
|
|
38
|
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
|
Thromb Haemost
|
2007
|
0.82
|
|
39
|
Rationale and design of the TAXUS Libertē Post-Approval Study: examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice.
|
Am Heart J
|
2012
|
0.82
|
|
40
|
Absence of "rebound" platelet hyperreactivity following cessation of prasugrel.
|
Thromb Haemost
|
2011
|
0.81
|
|
41
|
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
|
J Cardiovasc Pharmacol Ther
|
2007
|
0.81
|
|
42
|
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
|
Clin Pharmacokinet
|
2010
|
0.80
|
|
43
|
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
|
Br J Clin Pharmacol
|
2013
|
0.79
|
|
44
|
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
|
J Cardiovasc Pharmacol
|
2010
|
0.79
|
|
45
|
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
|
Thromb Haemost
|
2013
|
0.79
|
|
46
|
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
|
J Pediatr Hematol Oncol
|
2015
|
0.78
|
|
47
|
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
|
Platelets
|
2012
|
0.78
|
|
48
|
The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.
|
J Cardiovasc Pharmacol
|
2006
|
0.77
|
|
49
|
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
|
J Cardiovasc Pharmacol
|
2011
|
0.77
|
|
50
|
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
|
Thromb Haemost
|
2014
|
0.77
|
|
51
|
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
|
J Thromb Thrombolysis
|
2014
|
0.76
|
|
52
|
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
|
Platelets
|
2014
|
0.76
|
|
53
|
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.
|
Drugs Aging
|
2009
|
0.75
|
|
54
|
Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes.
|
J Clin Pharmacol
|
2010
|
0.75
|